Skip to main content

$0.049 0.007 (16.67%)

High

$0.05

Low

$0.04

Trades

74

Turnover

$48,318

Volume

1,094,468
30 June 2023 at 4:10pm
Register to track PXS and receive email alerts.

PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial

StockBot

416,823 posts

PXS released this announcement to the ASX on 5 October 2021, 8:33. The announcement is marked as price sensitive, and is 4 page(s) in length and 165.64kb in size.

You can view all announcements from PXS and see how they appear on a price chart on the announcements page.

At the date of this announcement, PXS was 0.000% short sold according to ASIC data. It was ranked the 672nd most shorted stock on the ASX. It remains ranked 672nd as of the latest reported data (12 July 2023).

Other Recent Announcements from PXS
Investor presentation 24 May 2023, 8:21
PXS Announces Encouraging Results from Phase 1c Scar Study 23 May 2023, 16:32
Trading Halt 22 May 2023, 8:56
PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial 5 October 2021, 8:33
Corporate Governance Statement 1 October 2021, 11:24
Appendix 4G 1 October 2021, 11:23
Notice of Annual General Meeting/Proxy Form 1 October 2021, 11:22
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track PXS and receive email alerts.